Eureka Therapeutics Appoints Dr. Jennifer F. Tseng to Scientific Advisory Board
Eureka Therapeutics has appointed surgical oncologist Dr. Jennifer F. Tseng to its Scientific Advisory Board.
Eureka, CA, November 3, 2026 —
Eureka Therapeutics, a company focused on developing novel immunotherapies, has announced the appointment of Dr. Jennifer F. Tseng to its Scientific Advisory Board. Dr. Tseng is a recognized expert in surgical oncology.
The addition of Dr. Tseng to the board signifies Eureka Therapeutics’ commitment to bolstering its scientific leadership and expertise. The Scientific Advisory Board plays a crucial role in guiding the company’s research and development strategies. The specific focus of Dr. Tseng’s advisory role within the board was not detailed in the announcement.
Dr. Tseng’s professional background includes significant contributions to the field of surgical oncology. Her expertise is expected to provide valuable insights as Eureka Therapeutics advances its pipeline of innovative treatments. The company’s work primarily involves the development of immunotherapies, a class of treatments that leverage the body’s own immune system to fight diseases, often cancer.
The appointment comes at a time when advancements in immunotherapy continue to shape the landscape of cancer treatment. Eureka Therapeutics aims to translate scientific discoveries into clinical applications, and advisory board members like Dr. Tseng are integral to this mission. The exact duration of Dr. Tseng’s tenure on the board was not disclosed.
Further details regarding the scope of the Scientific Advisory Board’s activities or specific projects Dr. Tseng will contribute to were not provided. Eureka Therapeutics continues to pursue its objective of developing next-generation therapies for patients with unmet medical needs.
Story summarized from the original created by Google News on news.google.com, see more information here.
